WBP1 Antibody

What is WBP1 and why is it important in cellular research?

WBP1 (WW domain binding protein 1) is a 32 kDa type I transmembrane protein that was originally identified in vitro as a protein binding to the WW domain of Yes kinase-associated protein. Research has established its biological significance in several key cellular processes, including the regulation of apoptosis and mitochondrial function. Notably, silencing of WBP1 with small hairpin RNAs causes partial but significant suppression of ATF6-induced apoptosis . Recent studies have also revealed WBP1's role in modulating mitochondrial function and ferroptosis, particularly in colorectal cancer (CRC) cells, suggesting its potential as a therapeutic target for chemoresistant disease .

What are the key specifications of commercially available WBP1 antibodies?

Commercial WBP1 antibodies are available with various specifications suited for different experimental applications. For example, the WBP1 antibody (11042-1-AP) is a rabbit polyclonal IgG antibody that targets WBP1 in Western blot (WB), immunohistochemistry (IHC), and ELISA applications. This antibody shows reactivity with human and mouse samples, with a molecular weight detection at 32 kDa. It is supplied in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) and recommended to be stored at -20°C, where it remains stable for one year after shipment .

What are the recommended validation strategies for WBP1 antibodies in Western blot applications?

For proper validation of WBP1 antibodies in Western blot applications, researchers should implement a multi-faceted approach to ensure specificity, selectivity, and reproducibility. As recommended in antibody validation literature, the antibody should produce consistent results within and between Western blotting experiments . A comprehensive validation protocol for WBP1 antibodies should include:

• Positive and negative controls: Using tissue samples with known WBP1 expression (e.g., mouse brain tissue) as positive controls .

• Knockout/knockdown validation: Employing CRISPR-Cas9 technology to generate WBP1 knockout lines for antibody specificity confirmation. Guide RNAs targeting WBP1 exon 4 can be cloned into appropriate vectors (e.g., pSpCas9(BB)-2A-Puro) .

• Orthogonal validation: Confirming the observed effect with a complementary method, such as mass spectrometry or PCR .

• Technical reproducibility: Ensuring consistent results across different experimental runs and laboratory conditions.

How should dilution optimization be performed for WBP1 antibodies in different experimental applications?

Dilution optimization is crucial for achieving optimal signal-to-noise ratios in various applications of WBP1 antibodies. Based on established protocols, the following dilution ranges are recommended:

• Start with a titration series spanning the recommended dilution range

• Test each dilution on relevant samples (e.g., mouse brain tissue for WB)

• Evaluate signal intensity, background levels, and specificity at each dilution

• Select the optimal dilution that provides maximum specific signal with minimal background

• Validate the chosen dilution across multiple experimental replicates to ensure reproducibility

For IHC applications specifically, antigen retrieval conditions may significantly impact antibody performance. For WBP1 antibody, TE buffer at pH 9.0 is suggested for antigen retrieval, with citrate buffer at pH 6.0 as an alternative option .

How can WBP1 antibodies be utilized to investigate mitochondrial localization and function?

WBP1 antibodies can be effectively employed to study mitochondrial localization and function using the following methodological approach:

Immunofluorescence co-localization studies can be performed by:

• Labeling mitochondria using MitoTracker Red CMXRos (500 nM) for 30 minutes at 37°C

• Fixing cells with 4% paraformaldehyde for 15 minutes

• Permeabilizing with 0.1% Triton X-100 for 10 minutes at room temperature

• Blocking with 5% bovine serum albumin for 1 hour

• Applying primary WBP1 antibody (1:100 dilution) overnight at 4°C

• Incubating with Alexa Fluor 488-conjugated secondary antibodies (1:500) for 1 hour

• Staining nuclei with DAPI (1 μg/mL) for 20 minutes

• Analyzing co-localization using confocal microscopy

To investigate WBP1's role in mitochondrial function, researchers can combine this approach with functional assays after WBP1 gene manipulation through CRISPR-Cas9 knockout or lentiviral overexpression systems, as described in recent colorectal cancer research .

What protocols are recommended for studying WBP1's role in cell proliferation and survival pathways?

To study WBP1's impact on cell proliferation and survival pathways, researchers can implement the following experimental protocol:

• Cell Line Manipulation:

  • Generate WBP1 knockout cell lines using CRISPR-Cas9 technology with guide RNAs targeting WBP1 exon 4

  • Create WBP1 overexpression models using lentiviral transduction with pLenti-CMV-Puro DEST vector containing human WBP1 cDNA

• Proliferation Analysis:

  • Seed cells at 2,000 cells/well in 96-well plates

  • Allow overnight adhesion

  • Use sulforhodamine B (SRB) assay for proliferation measurement:

    • Fix cells with 10% TCA at 4°C for 1 hour

    • Wash with water

    • Stain with 0.4% SRB solution for 30 minutes

    • Rinse with 1% acetic acid

    • Solubilize bound dye with 10mM Tris base (pH 10.5)

    • Measure absorbance at 565 nm

• Western Blot Analysis for Pathway Assessment:

  • Lyse cells in RIPA buffer with protease inhibitors

  • Quantify protein using BCA assay

  • Resolve 30 μg of protein by SDS-PAGE

  • Transfer to PVDF membranes

  • Block with 5% non-fat milk for 1 hour

  • Incubate with WBP1 antibody (1:1000) and other pathway-specific antibodies overnight at 4°C

  • Apply HRP-conjugated secondary antibodies for 1 hour

  • Visualize using enhanced chemiluminescence

This comprehensive approach allows for a detailed investigation of how WBP1 affects proliferation and connects to relevant signaling pathways.

How can researchers address potential cross-reactivity issues in WBP1 antibody experiments?

Cross-reactivity represents a significant challenge when working with antibodies, including those targeting WBP1. To address and minimize cross-reactivity issues, implement these methodological approaches:

• Validation through genetic models:

  • Utilize WBP1 knockout cell lines created through CRISPR-Cas9 technology as negative controls to identify non-specific bands or signals

  • Compare WBP1 overexpression models with wild-type cells to confirm specific signal enhancement

• Peptide competition assays:

  • Pre-incubate the WBP1 antibody with purified WBP1 protein or immunogen peptide

  • Run parallel Western blot or immunostaining with competed and non-competed antibody

  • Specific signals should be blocked in the competed samples

• Multi-antibody validation approach:

  • Use multiple antibodies targeting different epitopes of WBP1

  • Compare signal patterns across these antibodies

  • Concordant results from multiple antibodies increase confidence in specificity

• Orthogonal validation with mass spectrometry:

  • Perform immunoprecipitation using the WBP1 antibody

  • Analyze the precipitated proteins by mass spectrometry

  • Confirm WBP1 presence and identify potential cross-reactive proteins

What contradictions exist in the literature regarding WBP1 expression across different tissue types, and how might antibody-based studies address these?

The literature contains several unresolved questions regarding WBP1 expression patterns across different tissues and disease states. To address these contradictions methodologically:

• Systematic multi-tissue analysis:

  • Design a comprehensive tissue microarray (TMA) panel including normal and diseased tissues

  • Standardize IHC protocol using optimized WBP1 antibody dilution (1:50-1:500)

  • Employ digital pathology quantification to ensure objective assessment

  • Compare expression levels across tissue types with statistical rigor

• Correlation with genomic and transcriptomic data:

  • Combine antibody-based protein detection with RNA-seq or qPCR for WBP1 mRNA levels

  • Analyze potential post-transcriptional regulation mechanisms that might explain discrepancies

  • Use TCGA database analysis to examine WBP1 expression differences between normal and tumor tissues

• Technical standardization approach:

  • Document all experimental variables (fixation methods, antigen retrieval conditions, etc.)

  • Use consistent protocols across laboratories

  • Implement positive and negative controls for each tissue type

  • Consider the limitations of each antibody's epitope accessibility in different tissue contexts

How can WBP1 antibodies be utilized in research on ferroptosis and cancer drug resistance?

Recent research has revealed WBP1's role in ferroptosis regulation and cancer drug resistance, particularly in colorectal cancer. To investigate these areas, researchers can implement the following methodological framework:

• Ferroptosis pathway analysis:

  • Generate WBP1 knockout and overexpression cell models as described previously

  • Assess expression of ferroptosis markers (GPX4, FTH1) using Western blot analysis

  • Measure lipid peroxidation levels using C11-BODIPY or MDA assays

  • Evaluate cell sensitivity to ferroptosis inducers (e.g., erastin, RSL3) with and without ferroptosis inhibitors (ferrostatin-1, liproxstatin-1)

  • Correlate WBP1 expression levels with ferroptosis sensitivity

• Drug resistance studies:

  • Establish drug-resistant cancer cell lines through incremental drug exposure

  • Compare WBP1 expression between parental and resistant cell lines

  • Modulate WBP1 expression in resistant cells and assess restoration of drug sensitivity

  • Combine with clinical database analysis to correlate WBP1 expression with treatment outcomes in cancer patients

• Mechanistic investigation:

  • Perform co-immunoprecipitation using WBP1 antibodies to identify interaction partners

  • Conduct subcellular fractionation followed by Western blotting to track WBP1 localization

  • Evaluate metabolic changes (oxygen consumption, ATP production) associated with WBP1 expression

This comprehensive approach would significantly advance understanding of WBP1's role in ferroptosis and drug resistance mechanisms.

What considerations should researchers have when designing experiments to study WBP1 interactions with the Yes kinase-associated protein and ATF6-induced apoptosis?

When investigating WBP1's interactions with Yes kinase-associated protein and its role in ATF6-induced apoptosis, researchers should consider the following experimental design elements:

• Interaction studies methodology:

  • Co-immunoprecipitation: Use WBP1 antibodies to pull down protein complexes and probe for Yes kinase-associated protein

  • Proximity ligation assay: Visualize in situ protein interactions using antibodies against both WBP1 and Yes kinase

  • Bimolecular fluorescence complementation: Create fusion constructs to directly visualize interactions

  • Domain mapping: Generate truncated WBP1 constructs to identify specific interaction domains

• ATF6-induced apoptosis analysis:

  • Induce ER stress with appropriate stimuli (tunicamycin, thapsigargin) to activate ATF6

  • Measure apoptosis markers (caspase activation, PARP cleavage) in relation to WBP1 expression

  • Utilize RNA interference with carefully designed controls:

    • Multiple shRNA constructs targeting different WBP1 regions

    • Scrambled shRNA controls

    • Rescue experiments with shRNA-resistant WBP1 constructs

• Technical considerations:

  • Validate all antibodies using the strategies outlined in section 2.1

  • Include appropriate positive and negative controls for each experimental system

  • Consider the impact of cell type on WBP1 function, as its role may vary across different cellular contexts

  • Account for potential compensation mechanisms in knockout models through comprehensive pathway analysis

This systematic approach will provide robust insights into the specific molecular mechanisms of WBP1 in these important cellular processes.